Small Cell Lung Carcinoma Clinical Trial
Official title:
DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine Carcinomas
This study is open to adults with small cell lung cancer and other neuroendocrine tumours. The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find a suitable dose of BI 764532 that people with advanced cancer can tolerate when taken alone. 2 different doses of BI 764532 are tested in this study. Another purpose is to check whether BI 764532 can make tumours shrink. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. Participants are put into 2 groups randomly, which means by chance. One group gets dose 1 of BI 764532 and the other group gets dose 2 of BI 764532. Participants get BI 764532 infusions into a vein when starting treatment. If there is benefit for the participants and if they can tolerate it, the treatment is given up to the maximum duration of the study. During this time, participants visit the study site regularly. The total number of visits depends on how they respond to and tolerate the treatment. The first study visits include an over-night stay to monitor participants' safety. Doctors record any unwanted effects and regularly check the general health of the participants.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03963414 -
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
|
Phase 1 | |
| Active, not recruiting |
NCT04358237 -
Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.
|
Phase 1/Phase 2 | |
| Completed |
NCT02874664 -
A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT02397733 -
Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)
|
N/A | |
| Recruiting |
NCT01977235 -
Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT00759824 -
A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
|
Phase 2 | |
| Active, not recruiting |
NCT03568097 -
Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT02876081 -
Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex
|
Phase 2 | |
| Recruiting |
NCT06247605 -
A Phase IIII Study of AL8326 in Small Cell Lung Cancer
|
Phase 3 | |
| Recruiting |
NCT04996771 -
Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT03662074 -
Subsequent Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT03232593 -
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
|
||
| Recruiting |
NCT01941316 -
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients
|
Phase 1/Phase 2 | |
| Terminated |
NCT01574300 -
Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
|
||
| Recruiting |
NCT06131840 -
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05683977 -
A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.
|
||
| Recruiting |
NCT04620837 -
Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy
|
Phase 2 | |
| Recruiting |
NCT05329623 -
A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.
|
Phase 1 | |
| Active, not recruiting |
NCT04902872 -
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03849469 -
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
|
Phase 1 |